Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

#For patients

Written for adults considering a peptide as part of their health management.

Country deep-dive

What ipamorelin actually costs in the US

Ipamorelin has no FDA approval and no legal US pharmacy or insurance price. The only figures are grey-market, and here is what the low number signals.

28 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

What TB-500 actually costs in the UK

TB-500 has no UK licence, so there is no NHS price and no NICE appraisal. The only UK cost is grey-market research-chemical listings sold for research use.

27 Jul 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

Tesamorelin UK: price and NHS access

Tesamorelin has no MHRA authorisation and no NICE appraisal. No NHS route, no regulated UK price. Why the EU application was withdrawn and what it means.

27 Jul 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

Tirzepatide UK: NHS price and private costs

Mounjaro's NHS price is commercial-in-confidence. Private prescriptions run £149-£400/month by dose. Here is how NICE TA924 and TA1026 shape who pays what.

27 Jul 2026 · PeptideMethods Editorial Team · 8 min read
Country deep-dive

BPC-157 in the US: price and access

No FDA approval, no compounding pathway, no regulated price. What grey-market costs and the US regulatory picture look like for BPC-157.

27 Jul 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

What ipamorelin actually costs in the UK

Ipamorelin has no UK price because it is not a licensed medicine. No NHS cost, no private prescription rate, only grey-market listings and the risk behind them.

26 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

What CJC-1295 actually costs in the UK

CJC-1295 has no UK marketing authorisation, so there is no NHS price and no reimbursement. Here is what sets its grey-market cash cost.

25 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

CJC-1295 import rules in the UK

CJC-1295 has no MHRA marketing authorisation, so UK medicines law leaves no ordinary route to import it as a medicine. Here is what the rules say.

25 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Explainer

Combining GLP-1 drugs and tesamorelin

No trial has tested combining retatrutide, tirzepatide and tesamorelin, and here is why doing so without clinical supervision is a real risk.

25 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide for postpartum prediabetes

A Belgian trial is testing whether once-weekly semaglutide can stop postpartum prediabetes after gestational diabetes from becoming type 2 diabetes.

24 Jul 2026 · PeptideMethods Editorial Team · 3 min read
Explainer

What GLP-1 labels say is worth tracking

The semaglutide and tirzepatide labels name specific things to monitor on a GLP-1, and the list is not the one a weight graph suggests.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Retatrutide's overstimulated side effects

Forum users describe a wired, foggy feeling on retatrutide. Here is what the phase 2 trials recorded, and the large gap between that and anecdote.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read